Washington, D.C. 20549

_________________________

FORM 6-K

_________________________

Pursuant to rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

May 2, 2024

_________________________

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

_________________________

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F x Form 40-F o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________ Financial report for the period 1 January 2024 to 31 March 2024

Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024

•Operating profit increased by 27% in Danish kroner and by 30% at constant exchange rates (CER) to DKK 31.8 billion.

•Sales in North America Operations increased by 34% in Danish kroner (35% at CER). Sales growth in the US was positively impacted by gross-to-net sales adjustments related to prior years. Sales in International Operations increased by 8% in Danish kroner (11% at CER).

•Sales within Diabetes and Obesity care increased by 25% in Danish kroner to DKK 61.0 billion (27% at CER), mainly driven by GLP-1 diabetes sales growth of 30% in Danish kroner (32% at CER) and Obesity care growing by 41% in Danish kroner to DKK 11.0 billion (42% at CER). Rare disease sales decreased by 4% measured in Danish kroner (3% at CER).

•In the first quarter of 2024, Novo Nordisk successfully completed the FLOW kidney outcomes trial with semaglutide 1.0 mg. Further, Wegovy® was approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease, and Awiqli®, once-weekly insulin icodec, was recommended for EU approval.

•In February 2024, Novo Nordisk announced an agreement to acquire three fill-finish sites from Novo Holdings A/S in connection with a transaction where Novo Holdings A/S has agreed to acquire Catalent, Inc. Novo Nordisk expects that the acquisition will be completed towards the end of 2024.

•For the 2024 outlook, sales growth is now expected to be 19-27% at CER, and operating profit growth is now expected to be 22-30% at CER. Growth reported in Danish kroner is now expected to be in line with CER growth for both sales and operating profit.

Lars Fruergaard Jørgensen, president and CEO: "We are pleased with the sales growth in the first three months of 2024, driven by increased demand for our GLP-1-based diabetes and obesity treatments. More patients benefit from our innovative treatments, and the agreement to acquire the three Catalent manufacturing sites will enable us to serve significantly more people living with diabetes and obesity in the future. Within R&D, we are pleased with the positive results from the kidney outcomes trial with semaglutide and the label expansion for cardiovascular risk reduction for Wegovy® in the US."

The strategic aspirations are objectives that Novo Nordisk intends to work towards and are not a projection of Novo Nordisk's financial outlook or expected growth. Novo Nordisk intends to describe how its activities develop in relation to each of the four dimensions on an ongoing basis.

Performance highlights for the first three months of 2024 (blue indicates first-quarter developments)

These unaudited consolidated financial statements for the first three months of 2024 have been prepared in accordance

with IAS 34 ‘Interim Financial Reporting’ and additional Danish disclosure requirements for listed companies.

The accounting policies adopted in the preparation are consistent with those applied in the Annual Report 2023 of Novo

Nordisk.

Sales grew by 22% measured in Danish kroner and by 24% at CER in the first three months of 2024, driven by Diabetes care sales growth of 24% (CER) and Obesity care sales growth of 42% (CER). Rare disease sales decreased by 3% (CER). Sales growth has resulted in periodic supply constraints and related drug shortage notifications across a number of products and geographies. Sales growth in the US was positively impacted by gross-to-net sales adjustments related to prior years and the phasing of rebates in 2023.

Sales in Diabetes care increased by 22% measured in Danish kroner and by 24% at CER to DKK 49,930 million driven by growth of GLP-1-based products. Sales growth in the US was positively impacted by gross-to-net sales adjustments related to prior years. Novo Nordisk has improved the global diabetes value market share over the last 12 months to 34.0% from 32.2% in line with the aspiration of strengthening the Diabetes care leadership, aiming at reaching a global value market share of more than one-third in 2025. The market share increase was driven by market share gains in both North America Operations and International Operations.

In the following sections, unless otherwise noted, market data are based on moving annual total (MAT) from February 2023 and February 2024 provided by the independent data provider IQVIA. EMEA covers Europe, the Middle East and Africa; Region China covers mainland China, Hong Kong and Taiwan; Rest of World covers all other countries except for North America.

Diabetes care, development per geographical area						Novo Nordisk’s share of the total diabetes market (value, MAT)						Diabetes care, sales development
						February			February			Sales Q1 2024 DKK million			Growth at CER
						2024			2023
Global						34.0		%	32.2		%	49,930			24		%
North America Operations						35.4		%	33.8		%	28,680			34		%
			- The US			34.9		%	33.5		%	26,546			35		%
International Operations						28.4		%	26.6		%	21,250			12		%
			- EMEA *			30.4		%	29.1		%	10,942			10		%
			- Region China **			32.4		%	32.2		%	4,439			11		%
			- Rest of World ***			23.6		%	20.4		%	5,869			18		%

Source: IQVIA, February 2024 data. *Data for EMEA available for European markets and seven markets outside Europe representing approximately 90% of Novo Nordisk Diabetes care sales in the area. **Data for mainland China, excluding Hong Kong and Taiwan. *** Data for Rest of World available for seven markets representing approximately 70% of total Novo Nordisk’s Diabetes care sales in the area.

Sales of GLP-1-based products for type 2 diabetes (Rybelsus®, Ozempic® and Victoza®) increased by 30% measured in Danish kroner and by 32% at CER to DKK 34,982 million. The estimated global GLP-1 share of total diabetes prescriptions has increased to 6.2% compared with 4.9% 12 months ago. Novo Nordisk continues to be the global market leader in the GLP-1 segment with a 55.3% value market share.

GLP-1, development per geographical area						Novo Nordisk's share of the diabetes GLP-1 market (value, MAT)						GLP-1, sales development
						February			February			Sales Q1 2024 DKK million			Growth at CER
						2024			2023
Global						55.3		%	54.5		%	34,982			32		%
North America Operations						53.5		%	53.1		%	24,363			37		%
			- The US			52.5		%	52.1		%	22,469			37		%
International Operations						70.0		%	65.2		%	10,619			22		%
			- EMEA *			63.3		%	61.1		%	5,942			18		%
			- Region China **			78.2		%	66.9		%	1,403			10		%
			- Rest of World ***			85.6		%	75.6		%	3,274			38		%

Source: IQVIA, February 2024 data. *Data for EMEA available for European markets and seven markets outside Europe representing approximately 90% of Novo Nordisk GLP-1 sales in the area. **Data for mainland China, excluding Hong Kong and Taiwan. ***Data for Rest of World available for seven markets representing approximately 70% of total Novo Nordisk Diabetes care sales in the area. Note: the estimated GLP-1 share of prescriptions is based on volume packs from IQVIA. Volume packs are converted into full-year patients/prescriptions based on WHO assumptions for average daily doses or if not available, Novo Nordisk assumptions.

Rybelsus® sales increased by 15% measured in Danish kroner and by 17% at CER to DKK 5,013 million. Sales growth was driven by EMEA and Rest of World, partially countered by lower sales in North America. Sales in North America was negatively impacted by wholesaler inventory movements.

Ozempic® sales increased by 42% measured in Danish kroner and by 43% at CER to DKK 27,810 million. Sales growth was driven by both North America Operations and International Operations. Sales growth has resulted in periodic supply constraints and related drug shortage notifications across geographies.

Victoza® sales decreased by 23% measured in Danish kroner and by 22% at CER to DKK 2,159 million as the GLP-1 market is moving towards once-weekly treatments. The sales decline was mainly driven by EMEA.

Sales of GLP-1 diabetes products in North America Operations increased by 36% measured in Danish kroner and by 37% at CER. Sales growth was positively impacted by gross-to-net sales adjustments related to prior years and the phasing of rebates in 2023. Novo Nordisk is the market leader with a 53.5% value market share. The estimated GLP-1 share of total diabetes prescriptions has increased to 16.2% compared with 12.0% 12 months ago.

Sales of GLP-1 in the US increased by 37% at CER. The sales increase was driven by continued uptake of Ozempic®, partially offset by declining Rybelsus® and Victoza® sales. Ozempic® sales growth was negatively impacted by periodic supply constraints.

Sales growth in the US was driven by a prescription volume growth of the GLP-1 class around 15% in the first quarter of 2024 compared to the first quarter of 2023. Novo Nordisk is the market leader with 57.6% measured by total monthly prescriptions and 59.5% measured by new-to-brand prescriptions.

Sales of GLP-1 diabetes products in International Operations increased by 20% measured in Danish kroner and by 22% at CER. Sales growth is driven by all geographical areas. The estimated GLP-1 share of total diabetes prescriptions has increased to 3.9% compared with 3.2% 12 months ago. Novo Nordisk is the market leader with a value market share of 70.0% compared to 65.2% 12 months ago.

Sales in EMEA increased by 18% in both Danish kroner and at CER. The sales growth reflects the uptake of Ozempic® and Rybelsus®, partially offset by lower sales of Victoza®. Novo Nordisk remains the market leader in EMEA with a value market share of 63.3%. The estimated GLP-1 share of total diabetes prescriptions has increased to 5.3% compared with 4.5% 12 months ago.

Sales in Region China increased by 4% measured in Danish kroner and by 10% at CER. The sales growth mainly reflects the uptake of Ozempic®, partially countered by lower sales of Victoza®. GLP-1 sales growth was negatively impacted by periodic supply constraints. The GLP-1 share of total diabetes prescriptions has increased to 3.4% compared with 2.6% 12 months ago. Novo Nordisk is the market leader in Region China with a value market share of 78.2%.

Sales in Rest of World increased by 34% measured in Danish kroner and by 38% at CER. The sales growth reflects increased sales of Ozempic® and Rybelsus®, partially offset by lower sales of Victoza®. The estimated GLP-1 share of total diabetes prescriptions has increased to 2.5% compared with 1.9% 12 months ago. Novo Nordisk remains the market leader with a value market share of 85.6%.

Sales of insulin increased by 6% measured in Danish kroner and by 9% at CER to DKK 14,365 million. Sales growth in the US was positively impacted by gross-to-net sales adjustments in prior years.

Sales of insulin in North America Operations increased by 22% measured in Danish kroner and by 23% at CER. The sales increase in the US was positively impacted by gross-to-net sales adjustments in prior years, partially countered by a decline in volume. Novo Nordisk has a volume market share of 36.2% of the total US insulin market.

Sales of insulin in International Operations increased by 1% measured in Danish kroner and by 5% at CER. The sales increase at CER was driven by Region China, EMEA and Rest of World. Novo Nordisk has a volume market share of 48.0% of the total insulin market in International Operations.

Sales of insulin in EMEA remained unchanged in Danish kroner and increased by 1% at CER. The sales increase at CER was driven by long-acting insulin, partially countered by fast-acting insulin, human insulin and premix insulin. Novo Nordisk has a volume market share of 47.3% of the total insulin market.

Sales of insulin in Region China increased by 8% measured in Danish kroner and by 14% at CER. The sales increase was mainly driven by long-acting insulin and premix insulin, partially countered by human insulin. Novo Nordisk has a volume market share of 40.1% of the total insulin market.

Sales of insulin in Rest of World decreased by 3% measured in Danish kroner and increased by 1% at CER. The sales growth at CER was mainly driven by premix insulin and long-acting insulin, partially countered by human insulin and fast-acting insulin. Novo Nordisk has a volume market share of 57.6% of the total insulin market.

Sales of Obesity care products, Wegovy® and Saxenda®, increased by 41% measured in Danish kroner and by 42% at CER to DKK 11,035 million. Sales growth was driven by both North America Operations and International Operations. The volume growth of the global branded obesity market was 109% in the first quarter of 2024. Novo Nordisk is the global market leader with a volume market share of 85.4%.

Wegovy® sales increased by 106% measured in Danish kroner and by 107% at CER to DKK 9,377 million. Sales of Saxenda® decreased by 49% in both Danish kroner and CER to DKK 1,658 million as the obesity care market is moving towards once-weekly treatments.

Sales of Obesity care products in North America Operations increased by 42% measured in Danish kroner and by 44% at CER to DKK 8,418 million. Sales of Wegovy® increased by 86% measured in Danish kroner and by 88% at CER to DKK 8,233 million driven by increased volumes, partially countered by lower realised prices. Sales growth was positively impacted by the phasing of rebates in 2023. Demand for Wegovy® exceeds supply, and to safeguard continuity of care, supply of the lower Wegovy® dose strengths in the US has been reduced since May 2023. Novo Nordisk started gradually increasing the supply of the lower dose strengths in January 2024. Broad commercial formulary access has been achieved for Wegovy®. Wegovy® has more than 130,000 total weekly prescriptions and more than 25,000 weekly new-to-brand prescriptions.

Sales of Saxenda® decreased by 88% measured in Danish kroner and by 87% at CER to DKK 185 million as the obesity care market is moving towards once-weekly treatments. The volume growth of the branded obesity market in the US was 179%.

Sales of Obesity care products in International Operations increased by 36% measured in Danish kroner and by 35% at CER to DKK 2,617 million driven by increased sales in EMEA. Sales of Saxenda® in International Operations decreased by 18% in both Danish kroner and CER to DKK 1,473 million, and sales of Wegovy® reached DKK 1,144 million. Wegovy® has now been launched in ten countries in International Operations. The volume growth of the branded obesity market in International Operations was 48%.

Sales of Obesity care products in EMEA increased by 63% in both Danish kroner and at CER to DKK 1,977 million reflecting uptake of Wegovy® partially countered by declining sales of Saxenda®. The volume growth of the branded obesity market in EMEA was 76%.

Sales of Saxenda® in Rest of World decreased by 7% measured in Danish kroner and by 8% at CER to DKK 615 million. The volume growth of the branded obesity market in Rest of World was 5%.

Rare disease sales decreased by 4% measured in Danish kroner and by 3% at CER to DKK 4,384 million. Sales of rare blood disorder products decreased by 5% measured in Danish kroner and by 4% at CER to DKK 2,888 million driven by NovoSeven® and haemophilia A products, partially countered by increased haemophilia B sales. Sales of rare endocrine disorder products decreased by 1% measured in Danish kroner and increased by 1% at CER to DKK 1,113 million. Novo Nordisk is working on re-establishing supply of rare endocrine disorder products following a reduction of manufacturing output in 2022 and 2023. Sogroya® has been launched in five countries, and the initial feedback from patients and physicians is encouraging.

Rare disease sales in North America Operations increased by 19% measured in Danish kroner and by 20% at CER. The sales increase was driven by rare endocrine disorder products increasing by 74% measured in Danish kroner and by 76% at CER reflecting gross-to-net sales adjustments related to prior years in the US and the launch of Sogroya®. Sales of rare blood disorders products increased by 2% measured in Danish kroner and by 3% at CER driven by sales of haemophilia A and B products, partially countered by lower sales of NovoSeven®.

Rare disease sales in International Operations decreased by 19% measured in Danish kroner and by 18% at CER. The sales decline was driven by lower sales of rare endocrine disorder products, decreasing by 47% measured in Danish kroner and by 44% at CER, reflecting a reduction in manufacturing output. Sogroya® has now been launched in four countries in International Operations with encouraging initial feedback. Sales of rare blood disorder products decreased by 11% measured in Danish kroner and by 10% at CER driven by decreased sales of haemophilia A products and NovoSeven®, partially countered by haemophilia B sales.

Rare disease sales decreased by 5% in both Danish kroner and CER. Sales of rare blood disorder products decreased by 9% in both Danish kroner and CER, driven by NovoSeven® and haemophilia A products, partially countered by increased haemophilia B sales. The increased sales of haemophilia B products reflect the continued uptake of extended half-life products. Rare endocrine disorder products increased by 24% measured in Danish kroner and by 22% at CER.

Rare disease sales decreased by 77% in both Danish kroner and CER driven by both decreased sales of rare blood disorder products and rare endocrine products.

Rare disease sales decreased by 30% measured in Danish kroner and by 27% at CER. Sales of rare blood disorder products increased by 1% measured in Danish kroner and by 2% at CER driven by haemophilia A and B products, partially countered by lower sales of NovoSeven®. Sales of rare endocrine disorder products decreased by 66% measured in Danish kroner and by 62% at CER reflecting a reduction in manufacturing output.

Sales increased by 22% measured in Danish kroner and by 24% at CER to DKK 65,349 million in the first three months of 2024. Sales growth in the US was positively impacted by gross-to-net sales adjustments related to prior years and the phasing of rebates in 2023. Sales growth has resulted in periodic supply constraints and related drug shortage notifications across a number of products and geographies. In North America Operations, sales increased by 34% measured in Danish kroner and by 35% at CER. Sales in International Operations increased by 8% measured in Danish kroner and by 11% at CER.

Sales in North America Operations increased by 34% measured in Danish kroner and by 35% at CER. Sales growth in the US was positively impacted by gross-to-net sales adjustments related to prior years and the phasing of rebates in 2023. The sales increase reflects GLP-1 diabetes sales growing by 37% at CER and Obesity care sales growing by 44% at CER. GLP-1 diabetes sales growth was negatively impacted by periodic supply constraints. Insulin sales increased by 23% at CER reflecting gross-to-net sales adjustments related to prior years, partially countered by a decline in volume. Rare disease sales increased by 20% at CER driven by Rare endocrine disorders, mainly reflecting gross-to-net sales adjustments related to prior years and the launch of Sogroya®.

Sales in International Operations increased by 8% measured in Danish kroner and by 11% at CER. Sales growth was driven by GLP-1 diabetes sales growing by 22% at CER, Obesity care sales growing by 35% at CER and insulin sales growing by 5% at CER, partially countered by Rare disease sales decreasing by 18% at CER, reflecting a reduction in manufacturing output.

Sales in EMEA increased by 12% measured in Danish kroner and by 13% at CER. Sales growth was driven by Diabetes care growing by 10% at CER driven by GLP-1 diabetes sales growing by 18% at CER and insulin sales growing by 1% at CER. Obesity care sales increased by 63% at CER and Rare disease sales decreased by 5% at CER.

Sales in Region China increased by 1% measured in Danish kroner and by 7% at CER. The sales increase at CER was driven by insulin sales increasing by 14% at CER and GLP-1 diabetes sales growing by 10% at CER. GLP-1 sales growth was negatively impacted by periodic supply constraints. Other diabetes care sales decreased by 9% at CER. Rare disease sales decreased by 77% at CER.

Sales in Rest of World increased by 5% measured in Danish kroner and by 8% at CER. Sales growth was driven by Diabetes care growing by 18% at CER, reflecting increased GLP-1 diabetes and insulin sales, Obesity care sales decreasing by 8% at CER and Rare disease decreasing by 27% at CER.

The cost of goods sold increased by 21% in both Danish kroner and at CER to DKK 9,916 million, resulting in a gross margin of 84.8% measured in Danish kroner compared with 84.7% in the first three months of 2023. The increase in gross margin reflects a positive price impact due to gross-to-net sales adjustments in the US and a positive product mix, driven by increased sales of GLP-1-based treatments. This is partially countered by costs related to ongoing capacity expansions and a negative currency impact.

Sales and distribution costs increased by 7% measured in Danish kroner and by 8% at CER to DKK 13,256 million. The increase in costs is driven by both North America Operations and International Operations. In North America Operations, the cost increase is mainly driven by promotional activities related to Wegovy®. In International Operations, the increase is mainly related to promotional activities for Rybelsus® as well as Obesity care market development activities. Sales and distribution costs amounted to 20.3% as a percentage of sales.

Research and development costs increased by 28% in both Danish kroner and at CER to DKK 8,606 million reflecting increased late-stage clinical trial activity and increased early research activities compared to the first quarter of 2023. Research and development costs amounted to 13.2% as a percentage of sales.

Administration costs increased by 8% measured in Danish kroner and by 9% at CER to DKK 1,157 million. Administration costs amounted to 1.8% as a percentage of sales.

Other operating income and expenses (net) was a loss of DKK 568 million compared to an income of DKK 33 million in 2023. The loss is mainly reflecting impairments related to a partnership agreement of a company previously acquired by Novo Nordisk.

Operating profit increased by 27% measured in Danish kroner and by 30% at CER to DKK 31,846 million reflecting the sales growth.

Financial items (net) showed a net gain of DKK 72 million compared with a net loss of DKK 270 million in the first three months of 2023, mainly reflecting interest gains from cash and marketable securities.

In line with Novo Nordisk’s treasury policy, the most significant foreign exchange risks for Novo Nordisk have been hedged, primarily through foreign exchange forward contracts. The foreign exchange result was a loss of DKK 76 million compared with a net loss of DKK 209 million in the first quarter of 2023.

As per the end of March 2024, a negative market value of financial contracts of approximately DKK 1.2 billion has been deferred for recognition in 2024.

The effective tax rate was 20.4% in the first three months of 2024 compared with an effective tax rate of 19.9% in the first three months of 2023.

Net profit increased by 28% to DKK 25,407 million and diluted earnings per share increased by 29% to DKK 5.68.

Free cash flow realised in 2024 was DKK 5.0 billion compared to DKK 24.8 billion in the first three months of 2023. The lower free cash flow reflects phasing of rebates related to lower US gross sales in the first quarter of 2024 compared to the fourth quarter of 2023 combined with reduced insulin list prices as well as higher taxes paid and increasing capital expenditure. This is partially countered by an increase in net profit.

Income under the 340B Program has been partially recognised.

Capital expenditure for property, plant and equipment was DKK 8.5 billion compared with DKK 4.7 billion in 2023, primarily reflecting investments in additional capacity for active pharmaceutical ingredient (API) production and fill-finish capacity for both current and future injectable and oral products. Capital expenditures for intangible assets was DKK 0.5 billion in the first three months of 2024 compared with DKK 0.1 billion in 2023 reflecting business development activities.

In February 2024, Novo Nordisk announced an agreement to acquire three fill-finish sites from Novo Holdings A/S (Novo Holdings) in connection with a transaction where Novo Holdings has agreed to acquire Catalent, Inc. (Catalent), a global contract development and manufacturing organisation. The fulfilment of various customary closing conditions is progressing, and Novo Nordisk expects that the acquisition will be completed towards the end of 2024. For further information, please see company announcement here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=167017 (The contents of the company's website do not form a part of this Form 6-K).

Total equity was DKK 98,911 million at the end of March 2024, equivalent to 33.1% of total assets, compared with 31.9% at the end of March 2023. Please refer to appendix 5 for further elaboration of changes in equity. Novo Nordisk returned DKK 31.4 billion to shareholders via share buybacks (DKK 2.8 billion) and dividend (DKK 28.6 billion) in the first three months of 2024.

As of 30 April 2024, Novo Nordisk has repurchased 2,423,000 B shares of DKK 0.10 for an amount of DKK 2.1 billion as part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.

At the Annual General Meeting of Novo Nordisk A/S, held on 21 March 2024, a 1.0% reduction in the total share

capital was approved. The reduction was effectuated by a cancellation of 45,000,000 treasury B shares of DKK 0.10

at a nominal value of DKK 4,500,000. After the legal implementation of the share capital reduction on 24 April

2024, Novo Nordisk’s share capital now amounts to DKK 446,500,000 divided into an A share capital of DKK

107,487,200 and a B share capital of DKK 339,012,800.

The current expectations for 2024 are summarised in the table below:

Sales growth is now expected to be 19% to 27% at CER. Given the current exchange rates versus the Danish krone, sales growth reported in DKK is now expected to be in line with CER. The updated sales outlook at CER reflects gross-to-net sales adjustments related to prior years in the US.

The guidance reflects expectations for sales growth in both North America Operations and International Operations, mainly driven by volume growth of GLP-1-based treatments for Obesity and Diabetes care. Continued pricing pressure within Diabetes and Obesity Care are included in the guidance.

Following higher-than-expected volume growth in recent years, including GLP-1-based products such as Ozempic® and Wegovy®, combined with the expectation of continued volume growth and capacity limitations at some manufacturing sites, the outlook also reflects expected continued periodic supply constraints and related drug shortage notifications across a number of products and geographies. Novo Nordisk is investing in internal and external capacity to increase supply both short and long term. Novo Nordisk started gradually increasing the supply of the lower dose strengths of Wegovy® in the US in January 2024. A gradual roll-out of Wegovy® with capped volumes in International Operations is included in the guidance.

Operating profit growth is now expected to be 22% to 30% at CER. Given the current exchange rates versus the Danish krone, growth reported in DKK is expected to be in line with CER. The increased expectation for operating profit growth is reflecting the increased sales outlook, partially countered by an expected loss on Other operating income and expenses (net).

The expectation for operating profit growth primarily reflects the sales growth outlook and continued investments in future and current growth drivers within Research, Development and Commercial. Within R&D, investments are related to the continued expansion and progression of the early and late-stage pipeline. Commercial investments are mainly related to Obesity care market development activities as well as increased spend related to GLP-1 diabetes care.

Novo Nordisk now expects financial items (net) to amount to a loss of around DKK 0.7 billion, mainly reflecting losses associated with foreign exchange hedging contracts.

The effective tax rate for 2024 is still expected to be in the range of 19-21%.

Capital expenditure is still expected to be around DKK 45 billion in 2024 reflecting the expansion of the supply chain, including the previously communicated expansions of the manufacturing facilities in Kalundborg and Hillerød, Denmark, and Chartres, France. The investments in Kalundborg will create additional capacity across the entire global value chain

from manufacturing of active pharmaceutical ingredients (API) to packaging, with the majority invested in API capacity. The API facility will be designed as a multi-product facility with flexibility to accommodate current and future processes. In Hillerød, the investments will create additional production capacity of API within Cardiovascular & Emerging Therapy Areas. The expansion of the production facilities in Chartres are related to additional aseptic production and finished production processes. In the coming years, the capital expenditure to sales ratio is still expected to be low double-digit.

Depreciation, amortisation and impairment losses are still expected to be around DKK 10 billion.

The free cash flow is now expected to be DKK 57-67 billion reflecting the sales growth, a favourable impact from rebates in the US countered by investments in capital expenditure. The updated cash flow expectation reflects changes to gross-to-net sales estimates and related cash flow impacts as well as business development activities, including the planned acquisition of Cardior Pharmaceuticals GmbH.

Financial impacts related to and following the expected closing of the Catalent transaction have not been included in the financial guidance.

All of the above expectations are based on assumptions that the global or regional macroeconomic and political environment will not significantly change business conditions for Novo Nordisk during 2024, including energy and supply chain disruptions, the potential implications from major healthcare reforms and legislative changes as well as outcome of legal cases including litigations related to the 340B Drug Pricing Program in the US, and that the currency exchange rates, especially the US dollar, will remain at the current level versus the Danish krone. Neither does the guidance include the financial implications of any new significant business development transactions and significant impairments of intangible assets during 2024.

FX (average rates)																					Q1 2024			Q1 2023			% change			Spot rate 26 April 2024
USD																					687			694			(1		%)	696
CNY																					96			101			(5		%)	96
JPY																					4.63			5.24			(12		%)	4.44
CAD																					509			513			(1		%)	510
BRL																					139			134			4		%	135

Novo Nordisk has hedged expected net cash flows in a number of invoicing currencies and, all other things being equal, movements in key invoicing currencies will impact Novo Nordisk’s operating profit as outlined in the table below.

Key invoicing currencies			Impact on Novo Nordisk's operating profit in the next 12 months of a 5% movement in currency			Hedging period (months)1
USD			DKK 5,400 million			12
CNY2			DKK 560 million			12
CAD			DKK 520 million			6
BRL			DKK 250 million			0
JPY			DKK 210 million			12

1) As of 31 March 2024.

2) Chinese yuan traded offshore (CNH) used as proxy when hedging Novo Nordisk’s CNY currency exposure.

The financial impact from foreign exchange hedging is included in Financial items (net).

Awiqli® recommended for approval for the treatment of diabetes by the European regulatory authorities

In March 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending marketing authorisation for Awiqli® (the brand name for once-weekly basal insulin icodec) for treatment of diabetes in adults. Novo Nordisk expects to receive final marketing authorisation from the European Commission within approximately two months after the positive opinion. Awiqli® is approved in Switzerland and Canada. For further information, please see the company announcement here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=167035 (The contents of the company's website do not form a part of this Form 6-K).

In the first quarter of 2024, the US Food and Drug Administration (FDA) informed Novo Nordisk that an advisory committee will be convened in May 2024 to discuss the new drug application for once-weekly insulin icodec. The advisory committee is expected to evaluate the benefit-risk profile of insulin icodec in the treatment of type 1 diabetes.

In February 2024, Novo Nordisk successfully completed the second phase 3a trial, COMBINE 2, with IcoSema, a once-weekly combination of basal insulin icodec and semaglutide. The objective of the 52-week trial was to confirm the efficacy and safety of IcoSema compared with once-weekly semaglutide in people with type 2 diabetes inadequately controlled on GLP-1 treatment and in need of treatment intensification. The primary endpoint was met with IcoSema demonstrating superior reduction in HbA1c compared to once-weekly semaglutide 1.0 mg, with a 1.35 percentage points reduction for IcoSema and 0.9 percentage point reduction for semaglutide 1.0 mg from an overall baseline HbA1c of 8.0%. In the trial, IcoSema appeared to have a safe and well-tolerated profile.

In March 2024, Novo Nordisk announced the headline results from the kidney outcomes trial FLOW. Semaglutide 1.0 mg demonstrated 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial. In the trial, semaglutide 1.0 mg appeared to have a safe and well-tolerated profile in line with previous semaglutide 1.0 mg trials. In March 2024, Novo Nordisk submitted a label expansion application to the FDA. For further information, please see the company announcement here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=167028 (The contents of the company's website do not form a part of this Form 6-K).

In February 2024, Novo Nordisk successfully completed a phase 2 trial with higher doses of once-weekly subcutaneous semaglutide. The 40-week trial investigated efficacy and tolerability of 2, 8 and 16 mg semaglutide in around 245 people with type 2 diabetes. In the trial, dose response on weight loss was observed and the higher doses of semaglutide appeared to have a safe and well-tolerated profile in line with previous semaglutide trials. Following the completion of this phase 2 trial, semaglutide in higher doses are now being evaluated for further clinical development.

In April 2024, Novo Nordisk initiated a phase 2 trial with CagriSema, a once-weekly combination of 2.4 mg semaglutide and 2.4 mg cagrilintide, in chronic kidney disease. The 32-week trial is investigating efficacy and tolerability of CagriSema compared to the mono-components in approximately 620 people living with chronic kidney disease, type 2 diabetes and either overweight or obesity.

In March 2024, Novo Nordisk initiated two phase 2 trials with a subcutaneous once-weekly dual GIP/GLP-1 agonist. The 36-week trials are investigating safety and efficacy of different doses of GIP/GLP-1 in approximately 300 people living with diabetes as well as in approximately 350 people with obesity.

Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease

In March 2024, Wegovy® was approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease. The approval is based on the SELECT cardiovascular outcomes trial, which demonstrated that Wegovy® statistically significantly reduced the risk of MACE by 20% compared to placebo when added to standard of care. For further information, please see the company announcement here: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=167030 (The contents of the company's website do not form a part of this Form 6-K).

Novo Nordisk submitted the results from the STEP HFpEF trials for regulatory review in the US and EU in January 2024. In March 2024, the FDA granted the semaglutide 2.4 mg HFpEF supplement priority review with an action date in July 2024. The FDA informed Novo Nordisk that an advisory committee will be convened to discuss the supplement.

In April 2024, Novo Nordisk initiated a phase 3a, ATHENA, trial with Ziltivekimab in people with HFpEF and systemic inflammation. The 52-week trial is investigating functional outcomes and safety and is expected to enrol approximately 680 people. The heart failure outcomes trial, HERMES, was initiated in 2023 in people with HFpEF and inflammation.

In March 2024, Novo Nordisk initiated a phase 1 trial with an oral NRLP3 inhibitor, aiming for oral treatment in a broad range of liver, kidney and cardiometabolic diseases. The trial is investigating safety, tolerability, pharmacokinetics and biomarkers of the NRLP3 inhibitor.

In March 2024, Novo Nordisk agreed to acquire Cardior for up to EUR 1.025 billion, including an upfront payment and additional payments if certain development and commercial milestones are achieved. The agreement includes Cardior’s lead compound CDR132L, currently in phase 2 clinical development for the treatment of heart failure.

CDR132L is a synthetic antisense oligonucleotide and is designed to halt and partially reverse cellular pathology by selectively blocking abnormal levels of the microRNA molecule miR-132, potentially leading to long-lasting improvement in heart function. Novo Nordisk plans to initiate a second phase 2 trial that will investigate CDR132L in a chronic heart failure population with cardiac hypertrophy, a condition that causes the walls of the heart muscle to become thick and stiff, affecting the heart’s ability to pump blood. The acquisition is expected to be completed in the second quarter of 2024.

Novo Nordisk aims to reach zero CO2e emissions from operations and transportation by 2030. Further, the aim is that goods and services from suppliers will be based on 100% sourced renewable power by 2030. In the first quarter of 2024, through decarbonisation initiatives including increased usage of renewable energy and biofuel as well as reduced business flights, Novo Nordisk has reduced CO2e emissions from operations and transportation (Scope 1, 2 and partial Scope 3) by 31% compared to the first quarter of 2019.

Compared to the first three months of 2023, Scope 1 CO2e emissions increased by 6% reflecting increased production volumes, partially countered by energy saving initiatives and usage of renewable energy.

Scope 2 CO2e emissions increased by 20% compared to the first three months of 2023 reflecting the increase in number of employees and expansion of offices, partially countered by an increase in the usage of renewable energy sources.

Scope 3 CO2e emissions increased by 32% due to increased investments in capital expenditure for property, plant and equipment, partially countered by a decrease in emissions from product distribution, driven by the purchase of sustainable aviation fuel.

The number of people reached with Novo Nordisk products, across Diabetes and Obesity Care, was 41.8 million at the end of March 2024. This represents a net increase of 3.9 million patients compared to end of March 2023.

The Changing Diabetes® in Children programme aims to reach 100,000 children by 2030. By end of March 2024, more than 54,092 children were reached with diabetes care treatment, an increase of 26% compared to end of March 2023.

In January, Changing Diabetes in Children (CDiC) partnered with HemoCue, a global leader in point-of-care diagnostic testing, to enable CDiC to harmonise affordable HbA1c tests and improve outcomes for children with type 1 diabetes in all CDiC countries. The total number of CDiC countries now amount to 30 with a recent inclusion of Colombia.

After 10 years of building partnerships to address the root causes of type 2 diabetes in major cities across the globe, Cities Changing Diabetes is now transitioning to Cities for Better Health. The new programme will address health inequities and prevention of serious chronic diseases such as diabetes, obesity and heart disease globally. Through the programme, Novo Nordisk will double down on community-based prevention of diabetes, obesity and heart disease. The programme is active in 47 cities, across 25 countries, and comprising over 300 local, national and global partners.

Novo Nordisk aspires to be a sustainable employer, and in 2021, two aspirational gender diversity targets were launched: achieve a balanced gender representation across all managerial levels and achieve a minimum of 45% women and a minimum of 45% men in senior leadership positions by the end of 2025.

At the end of March 2024, 46% of all leaders were women and 41% of leaders in senior leadership positions were women, increasing from 45% and 39%, respectively, at the end of March 2023.

The number of full-time employees at the end of 2023 increased by 14% compared to 12 months ago. The total number of full-time employees was 66,015. The increase is mainly driven by Product Supply.

Novo Nordisk's key priorities are to safeguard employees and continue the supply of essential medicines to patients. Novo Nordisk is supporting humanitarian organisations in providing essential medicines to patients in the region.

Novo Nordisk's key priorities are to safeguard employees and continue the supply of essential medicines. In Ukraine, Novo Nordisk has continued the supply of medicines, which are currently broadly available throughout the country, also through collaboration with humanitarian organisations to provide access in bordering areas.

In Russia, Novo Nordisk's focus is solely on securing supply of insulin to ensure that patients can continue their treatment with essential medication. Sales in Russia and Ukraine constituted less than 1% of Novo Nordisk's global sales.

Novo Nordisk has received notifications from several manufacturers that they have filed Abbreviated New Drug Applications (ANDAs) with FDA for generic versions of Victoza® and Saxenda®. The ANDAs contain Paragraph IV certifications to obtain approval to engage in the commercial manufacture, use, or sale of such products before the expiration of some or all of the patents currently listed for those products in the Orange Book. Novo Nordisk has filed complaints for patent infringement against these manufacturers.

Novo Nordisk has entered into settlement agreements with several of the manufacturers. As part of the March 2019 settlement between Novo Nordisk and Teva Pharmaceuticals USA, Inc. (Teva) regarding Victoza®, Novo Nordisk has granted Teva a licence to sell an authorised generic version of Victoza® to the US market as of June 2024. All terms of the agreements are confidential. All agreements are reviewed by the U.S. Federal Trade Commission and the U.S. Department of Justice.

Novo Nordisk has also received notifications from several manufacturers that they have filed ANDAs with FDA for generic versions of Ozempic® and Wegovy®.

Novo Nordisk does not expect these matters to have a material impact on Novo Nordisk’s financial position, operating profit or cash flow.

The Board of Directors and Executive Management have reviewed and approved the financial report of Novo Nordisk A/S

for the first three months of 2024. The financial report has not been audited or reviewed by the company’s

independent auditors.

The financial report for the first three months of 2024 has been prepared in accordance with IAS 34 'Interim Financial

Reporting' and additional Danish disclosure requirements for listed companies. The accounting policies adopted in the

preparation are consistent with those applied in the Annual Report 2023 of Novo Nordisk.

In our opinion, the financial report for the first three months of 2024 gives a true and fair view of the Group’s assets,

liabilities and financial position at 31 March 2024, and of the results of the Group’s operations and cash flow for the

period 1 January 2024 to 31 March 2024. Furthermore, in our opinion, Management’s Review includes a true and fair

account of the development in the operations and financial circumstances of the results for the period and of the financial

position of the Group as well as a description of the most significant risks and elements of uncertainty facing the Group in

accordance with Danish disclosure requirements for listed companies.

Besides what has been disclosed in the quarterly financial report, no changes in the Group’s most significant risks and

uncertainties have occurred relative to what was disclosed in the consolidated Annual Report 2023.

Bagsværd, 2 May 2024

Executive Management:
Lars Fruergaard Jørgensen President and CEO			Karsten Munk Knudsen CFO
Board of Directors:
Helge Lund Chair			Henrik Poulsen Vice chair			Elisabeth Dahl Christensen
Laurence Debroux			Andreas Fibig			Sylvie Grégoire
Liselotte Hyveled			Mette Bøjer Jensen			Kasim Kutay
Christina Law			Martin Mackay			Thomas Rantzau

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube.

Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document as well as the company’s statutory Annual Report 2023 and Form 20-F both filed with the SEC in January 2024 in continuation of the publication of the Annual Report 2023, and written information released, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forward-looking statements. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to:

•statements of targets, plans, objectives or goals for future operations, including those related to Novo Nordisk’s products, product research, product development, product introductions and product approvals as well as cooperation in relation thereto,

•statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures,

•statements regarding future economic performance, future actions and outcome of contingencies such as legal proceedings, and

•statements regarding the assumptions underlying or relating to such statements.

In this document, examples of forward-looking statements can be found under the headings ‘Outlook’, ‘Research and Development update’ and 'Equity’.

These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors, including those described in this document, could cause actual results to differ materially from those contemplated in any forward-looking statements.

Factors that may affect future results include, but are not limited to, global as well as local political and economic conditions, such as interest rate and currency exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, including as a result of interruptions or delays affecting supply chains on which Novo Nordisk relies, shortages of supplies, including energy supplies, product recalls, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisk’s products, introduction of competing products, reliance on information technology including the risk of cybersecurity breaches, Novo Nordisk’s ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, strikes and other labour market disputes, failure to recruit and retain the right employees, failure to maintain a

culture of compliance, epidemics, pandemics or other public health crises, and the effects of domestic or international crises, civil unrest, war or other conflict, and factors related to the foregoing matters and other factors not specifically identified herein.

For an overview of some, but not all, of the risks that could adversely affect Novo Nordisk’s results or the accuracy of forward-looking statements in this document, reference is made to the overview of risk factors in ‘Risk Management’ of the Annual Report 2023.

Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this document, whether as a result of new information, future events or otherwise.

APPENDIX 1: QUARTERLY NUMBERS IN DKK

(Amounts in DKK million, except number of full-time equivalent employees, earnings per share and number of shares outstanding).
																																	% change
												2024						2023															Q1 2024 vs.
												Q1						Q4			Q3			Q2			Q1						Q1 2023
Net sales												65,349						65,863			58,731			54,300			53,367						22		%
Gross profit												55,433						55,849			49,018			46,444			45,185						23		%
Gross margin												84.8%						84.8%			83.5%			85.5%			84.7%
Sales and distribution costs												(13,256)						(17,170)			(12,819)			(14,342)			(12,412)						7		%
Percentage of sales												20.3%						26.1%			21.8%			26.4%			23.3%
Research and development costs												(8,606)						(10,460)			(8,128)			(7,127)			(6,728)						28		%
Percentage of sales												13.2%						15.9%			13.8%			13.1%			12.6%
Administrative costs												(1,157)						(1,456)			(1,256)			(1,072)			(1,071)						8		%
Percentage of sales												1.8%						2.2%			2.1%			2.0%			2.0%
Other operating income and expenses												(568)						3			98			(15)			33						N/A
Operating profit (EBIT)												31,846						26,766			26,913			23,888			25,007						27		%
Operating margin												48.7%						40.6%			45.8%			44.0%			46.9%
Financial income												2,146						(944)			3,318			(281)			852						152		%
Financial expenses												(2,074)						1,798			(2,168)			647			(1,122)						85		%
Financial items (net)												72						854			1,150			366			(270)						(127		%)
Profit before income taxes												31,918						27,620			28,063			24,254			24,737						29		%
Income taxes												(6,511)						(5,657)			(5,585)			(4,826)			(4,923)						32		%
Net profit												25,407						21,963			22,478			19,428			19,814						28		%
Depreciation, amortisation and impairment losses												2,914						2,992			2,525			2,177			1,719						70		%
Capital expenditure (PP&E)												8,474						9,407			5,828			5,878			4,693						81		%
Net cash generated from operating activities												14,314						9,551			40,966			28,577			29,814						(52		%)
EBITDA												34,760						29,758			29,438			26,065			26,726						30		%
Free cash flow												5,020						(7,250)			30,039			20,773			24,764						(80		%)
Total assets												298,921						314,486			300,101			280,753			250,025						20		%
Total equity												98,911						106,561			92,991			90,473			79,874						24		%
Equity ratio												33.1%						33.9%			31.0%			32.2%			31.9%
Full-time equivalent employees end of period												66,015						63,370			61,412			59,337			57,089						16		%
Basic earnings per share/ADR (in DKK)1												5.70						4.92			5.02			4.33			4.40						30		%
Diluted earnings per share/ADR (in DKK)1												5.68						4.91			5.00			4.32			4.39						29		%
Average number of shares outstanding (million)1												4,459.6						4,464.7			4,476.9			4,490.4			4,499.2						(1		%)
Average number of diluted shares outstanding (million)1												4,470.5						4,477.4			4,489.0			4,502.6			4,513.2						(1		%)
Sales by business segment:
Total GLP-1												34,982						37,761			30,635			27,925			26,811						30		%
Long-acting insulin												5,165						3,726			3,692			3,354			4,133						25		%
Premix insulin												2,968						2,123			2,219			2,456			2,776						7		%
Fast-acting insulin												4,487						4,142			3,808			3,511			4,488						0		%
Human insulin												1,745						1,989			1,626			1,967			2,012						(13		%)
Total insulin												14,365						11,980			11,345			11,288			13,409						7		%
Other Diabetes care												583						322			594			667			729						(20		%)
Total Diabetes care												49,930						50,063			42,574			39,880			40,949						22		%
Wegovy®												9,377						9,614			9,648			7,518			4,563						106		%
Saxenda®												1,658						1,615			2,607			2,788			3,279						(49		%)
Total Obesity care												11,035						11,229			12,255			10,306			7,842						41		%
Diabetes and Obesity care total												60,965						61,292			54,829			50,186			48,791						25		%
Rare blood disorders												2,888						2,934			2,957			2,836			3,049						(5		%)
Rare endocrine disorders												1,113						1,264			542			902			1,128						(1		%)
Other Rare disease												383						373			403			376			399						(4		%)
Rare disease total												4,384						4,571			3,902			4,114			4,576						(4		%)
Sales by geographic segment:
North America Operations												39,280						42,621			35,048			29,663			29,297						34		%
- The US												36,782						40,067			32,936			27,209			27,322						35		%
International Operations												26,069						23,242			23,683			24,637			24,070						8		%
- EMEA												14,326						12,706			12,563			12,856			12,742						12		%
- Region China												4,506						3,418			4,341			4,467			4,461						1		%
- Rest of World												7,237						7,118			6,779			7,314			6,867						5		%
Segment operating profit:
Diabetes and Obesity care												31,218						26,032			26,721			22,707			24,163						29		%
Rare disease												628						734			192			1,181			844						(26		%)

APPENDIX 2: INCOME STATEMENT AND STATEMENT OF COMPREHENSIVE INCOME

DKK million			Q1 2024						Q1 2023
Income statement
Net sales			65,349						53,367
Cost of goods sold			(9,916)						(8,182)
Gross profit			55,433						45,185
Sales and distribution costs			(13,256)						(12,412)
Research and development costs			(8,606)						(6,728)
Administrative costs			(1,157)						(1,071)
Other operating income and expenses			(568)						33
Operating profit			31,846						25,007
Financial income			2,146						852
Financial expenses			(2,074)						(1,122)
Profit before income taxes			31,918						24,737
Income taxes			(6,511)						(4,923)
NET PROFIT			25,407						19,814
Basic earnings per share (DKK)1			5.70						4.40
Diluted earnings per share (DKK)1			5.68						4.39
Segment Information
Segment sales:
Diabetes and Obesity care			60,965						48,791
Rare disease			4,384						4,576
Segment operating profit:
Diabetes and Obesity care			31,218						24,163
Operating margin			51.2%						49.5%
Rare disease			628						844
Operating margin			14.3%						18.4%
Total segment operating profit			31,846						25,007
Statement of comprehensive income
Net profit			25,407						19,814
Other comprehensive income
Remeasurements of defined benefit obligations			(73)						39
Items that will not be reclassified subsequently to the income statement			(73)						39
Exchange rate adjustments of investments in subsidiaries			425						(969)
Cash flow hedges:
Realisation of previously deferred (gains)/losses			(1,612)						(1,026)
Deferred gains/(losses) incurred during the period			(1,247)						2,238
Other items			(2)						3
Income tax related to these items			575						(341)
Items that will be reclassified subsequently to the Income statement			(1,861)						(95)
Other comprehensive income			(1,934)						(56)
TOTAL COMPREHENSIVE INCOME			23,473						19,758

APPENDIX 3: CASH FLOW STATEMENT

DKK million			Q1 2024						Q1 2023
Net profit			25,407						19,814
Adjustment for non-cash items:
Income taxes in the Income Statement			6,511						4,923
Depreciation, amortisation and impairment losses			2,914						1,719
Other non-cash items			118						20,230
Change in working capital			(8,852)						(10,216)
Interest received			480						188
Interest paid			(140)						(165)
Income taxes paid			(12,124)						(6,679)
Net cash generated from operating activities			14,314						29,814
Purchase of intangible assets			(535)						(108)
Purchase of property, plant and equipment			(8,474)						(4,693)
Proceeds from other financial assets			—						33
Purchase of other financial assets			(15)						(7)
Purchase of marketable securities			(1,145)						(2,354)
Sale of marketable securities			14,125						482
Net cash used in investing activities			3,956						(6,647)
Purchase of treasury shares			(2,836)						(5,199)
Dividends paid			(28,557)						(18,337)
Repayment of borrowings			(317)						(478)
Withheld dividend tax			5,328						3,393
Net cash used in financing activities			(26,382)						(20,621)
Net cash generated from activities			(8,112)						2,546
Cash and cash equivalents at the beginning of the year			14,392						12,653
Exchange gain/(loss) on cash and cash equivalents			44						(263)
Cash and cash equivalents at the end of the period			6,324						14,936